Pdt Partners, LLC Biocryst Pharmaceuticals Inc Transaction History
Pdt Partners, LLC
- $1.01 Billion
- Q1 2024
A detailed history of Pdt Partners, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Pdt Partners, LLC holds 380,523 shares of BCRX stock, worth $2.35 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
380,523
Previous 311,198
22.28%
Holding current value
$2.35 Million
Previous $1.86 Million
3.7%
% of portfolio
0.19%
Previous 0.21%
Shares
9 transactions
Others Institutions Holding BCRX
# of Institutions
258Shares Held
182MCall Options Held
839KPut Options Held
816K-
Black Rock Inc. New York, NY18.4MShares$114 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.7MShares$109 Million0.0% of portfolio
-
State Street Corp Boston, MA17.5MShares$108 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY13.1MShares$80.6 Million0.8% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$62.6 Million0.65% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.15B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...